Department of Intensive Care, Seoul National University Hospital, Seoul, Republic of Korea.
Department of Neurosurgery, Yeungnam University Hospital, Yeungnam University College of Medicine, Daegu, Republic of Korea.
Ann Med. 2022 Dec;54(1):3136-3145. doi: 10.1080/07853890.2022.2140449.
Nonfunctioning pituitary adenoma is a primary benign brain neoplasm and the transsphenoidal approach is known for a safe and effective first-line surgical treatment for pituitary tumours. The aim of this study was to retrospectively analyse the outcomes of the transsphenoidal approach for nonfunctioning pituitary adenomas treated at a single institute.
A total of 181 patients who underwent transsphenoidal approach with nonfunctioning pituitary adenoma at a single institute from March 1998 to November 2018 were included in this study. Ninety-six (53.0%) men and 85 (47.0%) women aged 21-79 years were included. The median outpatient follow-up duration was 58 months, and the median magnetic resonance imaging follow-up duration was 54 months. We assessed the surgical and clinical outcomes, complications, hormonal outcomes and recurrence tendency.
The overall total resection rate of a transsphenoidal approach for nonfunctioning pituitary adenoma was 84.0%. Visual impairment was improved after surgery in 115 (93.5%) of 123 patients. Of the 80 patients who complained of preoperative endocrine dysfunction, 62 (77.5%) patients recovered normal postoperative endocrine function. Diabetes insipidus, which occurred in 22 (12.2%) patients, was the most common complication. A total of 21 (11.6%) patients showed recurrence on average 57.6 months after surgery. The average recurrence period after surgery was 96.3 months in the total resection group of 6 patients and 42.1 months in the subtotal resection group of 15 patients. In multivariate analysis, the extent of resection was identified as a significant predictor of tumour recurrence with a hazard ratio of 6.093 and a -value of 0.002.
It is meaningful to report long-term surgical results within a single institution, and through this, it was reconfirmed that transsphenoidal approach is an effective and safe treatment for nonfunctioning pituitary adenoma. Long-term follow-up is required due to the possibility of recurrence. In addition, performing total resection during surgery helps to lower the risk of recurrence.KEY MESSAGESTranssphenoidal approach is an effective and safe treatment modality for pituitary adenoma.Complete resection is a significant predictor for the recurrence of pituitary adenomaLong-term follow-up is necessary for the treatment of nonfunctioning pituitary adenomas.
无功能垂体腺瘤是一种原发性良性脑肿瘤,经蝶窦入路是治疗垂体瘤的安全有效的一线手术治疗方法。本研究旨在回顾性分析单中心经蝶窦入路治疗无功能垂体腺瘤的结果。
本研究纳入了 1998 年 3 月至 2018 年 11 月期间在单中心接受经蝶窦入路治疗的 181 例无功能垂体腺瘤患者。患者包括 96 例男性(53.0%)和 85 例女性(47.0%),年龄 21-79 岁。中位门诊随访时间为 58 个月,中位磁共振成像随访时间为 54 个月。我们评估了手术和临床结果、并发症、激素结果和复发倾向。
经蝶窦入路治疗无功能垂体腺瘤的总全切除率为 84.0%。123 例视力障碍患者中有 115 例(93.5%)术后视力改善。80 例术前内分泌功能障碍患者中,62 例(77.5%)患者术后恢复正常内分泌功能。最常见的并发症是 22 例(12.2%)患者发生的尿崩症。21 例(11.6%)患者平均在术后 57.6 个月后复发。6 例完全切除组患者的平均复发期为术后 96.3 个月,15 例次全切除组患者的平均复发期为 42.1 个月。多因素分析显示,切除范围是肿瘤复发的显著预测因素,风险比为 6.093,a 值为 0.002。
报告单中心的长期手术结果是有意义的,通过这一结果再次证实,经蝶窦入路是治疗无功能垂体腺瘤的一种有效且安全的治疗方法。由于存在复发的可能性,需要进行长期随访。此外,术中进行全切除有助于降低复发风险。
关键信息
经蝶窦入路是治疗垂体腺瘤的有效且安全的治疗方法。
完全切除是垂体腺瘤复发的显著预测因素。
无功能垂体腺瘤的治疗需要长期随访。